Shares of CorMedix Inc. (CRMD) surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an upward revision of its full-year guidance.

The biopharma company reported a third-quarter earnings per share (EPS) of $1.26, significantly beating the analyst consensus estimate of $0.65. Net income for the quarter stood at $108.6 million, nearly doubling the expected $54.7 million. CorMedix's strong performance was largely driven by higher-than-anticipated sales of its flagship product, DefenCath, which contributed $88.8 million to the quarter's net revenue of $104.3 million.

In light of the robust quarterly performance, CorMedix raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million. The company also increased its 2025 pro forma adjusted EBITDA guidance to between $220 million and $240 million. This optimistic outlook, coupled with the strong Q3 results, has fueled investor enthusiasm, leading to the significant pre-market stock price jump.